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Objective: Because it is difficult to predict the behavior of thymomas on the basis
of morphology alone, other methods for determining tumor aggressiveness must be
explored. This study investigated the correlation between angiogenic grade and
invasiveness in thymic epithelial tumors.
Methods: Immunohistochemical studies of 46 surgically resected thymic epithelial
tumors (18 noninvasive thymomas, 20 invasive thymomas, and 8 thymic carcino-
mas) were conducted. To highlight the microvessels, we used a specific monoclonal
antibody against factor VIII. Expression of vascular endothelial growth factor and
basic fibroblast growth factor was determined by using polyclonal antibodies.
Results: Mean microvessel density readings for noninvasive thymomas, invasive
thymomas, and thymic carcinomas were 4.6  3.2, 12.4  7.5, and 34.4  16.7,
respectively. Stages I, II, III, and IV of thymoma had microvessel density readings
of 4.6  3.2, 8.5  4.3, 13.8  7.7, and 22.0  6.8, respectively. These findings
suggest a significant correlation between microvessel density and tumor invasive-
ness. Vascular endothelial growth factor expression in noninvasive thymomas,
invasive thymomas, and thymic carcinomas was present in 1 (5.6%) of 18, 11
(55.0%) of 20, and 5 (62.5%) of 8 patients, respectively, thereby indicating a distinct
association between vascular endothelial growth factor expression and increased
microvessel density. Basic fibroblast growth factor expression was present in only
8 patients.
Conclusions: In patients with thymic epithelial tumors, there appears to be a
significant correlation between tumor angiogenesis and invasiveness. Furthermore,
our data suggests that this angiogenesis in thymic epithelial tumors might be, at least
in part, dependent on vascular endothelial growth factor expression.
Although thymic carcinomas show typical features of malignancy,thymomas are more difficult to classify. There are 2 groups:noninvasive thymomas and invasive thymomas.1 Cytologically,these groups are unremarkable, making it difficult to distinguishbetween them. The majority of thymomas are encapsulated tu-mors that behave in a benign fashion and are therefore not
invasive. Even though a thymoma occasionally invades surrounding structures or
even metastasizes to thoracic or extrathoracic organs, it retains its cytologically
benign features. It is therefore difficult to predict the behavior of thymomas on the
basis of morphology alone.2-4 However, tumor invasiveness is regarded as the most
important factor affecting survival in thymoma.5 Therefore the most important
From the Department of Surgery II,
Miyazaki Medical College, Kiyotake,
Miyazaki, Japan.
Received for publication Aug 16, 2001; re-
visions requested Nov 28, 2001; revisions
received Feb 1, 2002; accepted for publica-
tion Feb 6, 2002.
Address for reprints: Masaki Tomita, MD,
PhD, Kihara 5200, Kiyotake, Miyazaki,
889-1692, Japan (E-mail: mtomita@post.
miyazaki-med.ac.jp).
J Thorac Cardiovasc Surg 2002;124:493-8
Copyright © 2002 by The American Asso-
ciation for Thoracic Surgery
0022-5223/2002 $35.000 12/1/124389
doi:10.1067/mtc.2002.124389
Tomita et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 124, Number 3 493
G
TS
prognostic factor for thymomas is their macroscopic appear-
ance at the operation, and Masaoka staging (I-IV) is useful
in staging patients with thymoma.5
Previous studies have linked tumor aggressiveness to
Ki67,6 epidermal growth factor receptor,6 bcl-2,7 argyro-
philic nucleolar organizer region,8 and matrix metallopro-
teinase 2 activation9 in thymic epithelial tumors.
Because the functional relationship between tumor-in-
duced angiogenesis and tumor invasion is generally ac-
cepted with regard to cancerous tissue,10 we hypothesized
that there might be a correlation between angiogenic grade
and invasiveness in thymic epithelial tumors. To prove this
hypothesis, we investigated tumor angiogenesis and also
assessed the expression of vascular endothelial growth fac-
tor (VEGF) and basic fibroblast growth factor (bFGF),
pivotal mediators of tumor angiogenesis.
Materials and Methods
Patients and Tissue Samples
Forty-six consecutive patients (17 men and 29 women) with thy-
mic epithelial tumors who were treated surgically at Miyazaki
Medical College were included in this study. Patient ages ranged
from 19 to 77 years (mean, 55.2 years). The Masaoka staging
system5 was followed to assign postoperative staging of thymo-
mas. Thymomas were divided into 2 groups on the basis of
surgical and histologic findings as follows: noninvasive thymoma,
clinical stage I; invasive thymoma, clinical stages II, III, or IV.
This classification was mainly done on the basis of the macro-
scopic appearance of the tumor at the time of operations by 2 or
more surgeons. The tumors included 18 noninvasive thymomas, 20
invasive thymomas, and 8 thymic carcinomas. Fourteen patients (7
with noninvasive and 7 with invasive thymomas) had concomitant
myasthenia gravis (MG), and 2 patients (1 with noninvasive and 1
with invasive thymomas) had pure red cell aplasia. Table 1 sum-
marizes the clinical characteristics of these patients. Surgically
resected tissue samples previously fixed in formalin and embedded
in paraffin were used in this study.
Immunohistochemical Studies
To highlight the microvessels, we used a specific monoclonal
antibody against factor VIII (Dako Diagnostika, Hamburg, Ger-
many). To determine VEGF and bFGF expression, we used poly-
clonal antibodies against VEGF (Santa Cruz Biotechnology, Santa
Cruz, Calif) and bFGF (Santa Cruz Biotechnology). Before stain-
ing, serial 4-m-thick sections were pretreated with microwave
heating in 10 mmol/L citric acid buffer for 4  5 minutes. These
sections were immersed in 0.6% H2O2 in methanol for 20 minutes
at room temperature to block endogenous peroxidase activity.
After blocking nonspecific protein binding with an overnight in-
cubation with Block Ace (Dainippon, Inc, Osaka, Japan), the
sections were incubated with primary antibodies against human
factor VIII (1:200), VEGF (1:100), and bFGF (1:100), respec-
tively, at 4°C overnight. Subsequently, sections were incubated
with the secondary antiserum (1:500) for 1 hour, followed by an
incubation with peroxidase-antiperoxidase complex for 30 minutes
at room temperature. The sections were visualized with a diami-
nobenzidine/metal concentration (10) and stable peroxide sub-
strate buffer (1) system (Pierce, Rockford, Ill). The sections were
then washed with water and counterstained with hematoxylin.
Immunohistologic results were assessed semiquantitatively by 2
authors. Microvessel density was determined, as described by
Weidner and colleagues,11 in the area of the most intense vascu-
larization (hot spot) of each tumor, and the average count was
recorded. VEGF expression was evaluated as described in our
previous study.12 Tumors in which greater than 30% of the tumor
cells stained more intensely than normal smooth muscle were
judged to be VEGF positive. Basic FGF antibody reactivity with
individual tissue sections was considered positive if unequivocal
staining of the membrane or cytoplasm was observed.13
Statistical Analysis
Data for the groups were compared by using the 2-tailed indepen-
dent Student t test. Correlation trends were assessed by using the
Spearman rank correlation coefficient.
Results
Microvessel Count
At a magnification of 200, microvessels appeared as
brown linear fragments; occasionally, a nucleus was visible.
Tiny lumens within these microvessels often resembled
small circular or fusiform structures (Figure 1). In noninva-
sive thymomas (group NT) microvessels were predomi-
nantly observed in small groups at the margin of the tumor
and rarely seen in the tumor parenchyma. In invasive thy-
momas (group IT) and thymic carcinomas (group TC),
however, microvessels were present in the tumor paren-
chyma in addition to those observed at the margin. The
number (mean  SD) of microvessels (per 200 field) in
groups NT, IT, and TC was 4.6  3.2, 12.4  7.5, and
34.4  16.7, respectively. As shown in Figure 2, these data
demonstrate a significant correlation between microvessel
density and invasiveness (Spearman rank correlation: r
value  0.793, P  .0001).
The number (mean  SD) of microvessels (per 200








Male 5 10 2
Female 13 10 6
Stage
I 18 - -
II - 10 -
III - 7 -
IV - 3 -
Myasthenia gravis
 7 7 0
 11 13 8
Pure red cell aplasia
 1 1 0
 17 19 8
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field) of thymomas in stages I, II, III, and IV (as determined
with the Masaoka staging system) was 4.6 3.2, 8.5 4.3,
13.1 7.7, and 22.0 6.8, respectively. These data (Figure
3) suggest a definite correlation between microvessel den-
sity and clinical stage of thymomas (Spearman rank corre-
lation: r value  0.727, P  .0001).
The microvessel count (per 200 field, mean  SD) in
patients with MG was 8.0  5.2; in patients without the
disease, the count was 14.0 14.9. These results suggest an
inverse association between the presence of MG and mi-
crovessel density (P  .019). We did not demonstrate any
correlation between the presence of pure red cell aplasia and
microvessel density (P  .75).
VEGF and bFGF Expression
VEGF-positive staining was predominantly observed in the
cytoplasm of the tumor cells. VEGF expression in groups
NT, IT, and TC was 1 (5.6%) of 18, 11 (55.0%) of 20, and
5 (62.5%) of 8 patients, respectively. These results indicate
a definite correlation between VEGF expression and inva-
siveness (Spearman rank correlation: r value  0.672, P 
.0001). Furthermore, as shown in Figure 4, our data suggest
an association between VEGF expression and microvessel
density (P  .003).
Basic FGF immunoreactivity was also shown to be cy-
toplasmic. Because, in the present study, bFGF expression
was detected in only 8 patients (0 in group NT, 5 in group
IT, and 3 in group TC), the relationship between bFGF
expression and thymic tumor invasiveness was not evalu-
ated. We did, however, demonstrate a correlation between
bFGF expression and microvessel density (P .04, data not
shown).
Discussion
Distinguishing between noninvasive and invasive thymo-
mas by means of histologic examination alone is difficult
Figure 1. Immunohistochemical staining of microvessels in noninvasive thymoma (A1 and A2), invasive thymoma
(B1 and B2), and thymic carcinoma (C1 and C2). Microvessels were observed at the edge of the tumor (A1, B1, and
C1). Microvessels were also seen in the parenchyma of invasive thymoma (B2) and thymic carcinoma (C2) but not
in noninvasive thymoma (A2). (Original magnification 100.)
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because the morphology of the 2 types does not differ
significantly. The most important prognostic indicator is the
macroscopic appearance of the thymoma at the time of the
operation (ie, irrespective of whether it is encapsulated).14,15
Because angiogenesis is essential for tumor growth,16 an
enhanced vascular supply could reflect a malignant poten-
tial. Blood vessels might play an important role in tumoro-
genesis by supplying nutrients and oxygen and disposing of
metabolic waste products, thereby allowing tumor invasion.
Although numerous studies regarding tumor angiogenesis in
human cancers have been published, they do not address
angiogenesis in thymic epithelial tumors. In our study we
assessed the relationship between angiogenic grade and
invasiveness in thymic epithelial tumors. Our data indicate
a significant correlation between tumor angiogenesis and
invasiveness in thymic epithelial tumors. Thymic carcino-
mas are different types of tumors than thymomas, and they
have more aggressive histologic appearances and clinical
outcome than those of thymomas. It has been unknown
whether angiogenesis of thymic carcinomas is more aggres-
sive than that of thymomas. Therefore we included thymic
carcinoma and found that thymic carcinomas have more
aggressive angiogenic function than thymomas. In addition,
we demonstrated the presence of parenchymal microvessels
in invasive thymoma but not in noninvasive thymoma. This
suggests it might be possible to distinguish between these 2
groups on the basis of the presence or absence of parenchy-
mal microvessels. Further studies in this area are warranted.
It was reported that World Health Organization (WHO)
histologic classification reflects the clinical features of thy-
mic epithelial tumors.17 Our recent data indicated a trend
toward an association between WHO histologic classifica-
tion and tumor angiogenesis in thymic epithelial tumors;
however, it did not reach statistical significance (unpub-
lished data). Whether microvessel density in thymic epithe-
lial tumor is related to WHO histologic classification war-
rants further investigation.
Figure 2. Microvessel density in noninvasive thymoma, invasive
thymoma, and thymic carcinoma (Spearman rank correlation: r
value  0.793, P < .0001).
Figure 3. Relationship between microvessel density and clinical
stage in thymoma. (Spearman rank correlation: r value  0.727,
P < .0001).
Figure 4. Relationship between microvessel density and VEGF
expression (P  .003).
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Angiogenesis is controlled by angiogenic factors that
regulate the coordinated extracellular matrix remodeling,
endothelial cell proliferation, capillary differentiation, and
anastomosis necessary to establish a blood supply.18,19
Matrix metalloproteinases, the main function of which is
to degrade extracellular matrix, are thought to play a role
not only in tumor invasion but also in angiogenesis.20
Although factors that induce tumor angiogenesis in thy-
mic epithelial tumors have not been clearly defined,
Kondo and coworkers9 reported a correlation between
matrix metalloproteinase 2 activation and invasiveness in
thymic epithelial tumors. This study suggests that matrix
metalloproteinase 2 might be an inducer of angiogenesis
in these types of tumors.
VEGF, a specific mitogen for endothelium, increases
vascular permeability and induces proteolytic enzymes
necessary for vascular remodeling.21 Our data indicate a
definite association between VEGF expression and inva-
siveness in thymic epithelial tumors. More importantly,
because of a strong correlation between VEGF expres-
sion and microvessel density, angiogenesis in thymic
epithelial tumors might be, at least in part, dependent on
VEGF expression.
Basic FGF is also an important angiogenesis inducer.22
Although we demonstrated a relationship between bFGF
expression and microvessel density, bFGF-positive patients
accounted for only 8 (17.4%) of 46 patients in our study. On
the basis of these numbers, it seems likely that angiogenesis
of thymic epithelial tumors is less dependent on the pres-
ence of bFGF.
Interestingly, although our results showed an inverse
association between the presence of MG and microvessel
density, the number of patients with MG in group NT was
essentially the same as for those in group IT (Table 1). In
addition, it has been reported that MG can no longer be
considered an adverse prognostic factor in thymoma.23
Taken together, the presence of MG might not be indicative
of tumor invasiveness and subsequent patient survival. Fur-
thermore, it has been proposed that thymomas associated
with MG might be initiated by an immune reaction against
a tumor protein related to or cross-reactive with the acetyl-
choline receptor.24 Whether microvessel density in MG-
associated thymomas is related to this immune reaction
warrants further investigation.
It had been reported that antiangiogenic agents have been
emphasized as potential therapeutic agents for patients with
malignancies.25 Furthermore, it had also been reported that
anti-VEGF therapy significantly inhibited the growth of
established experimental tumors.26 Thus, taken together
with our data, antiangiogenic agents might be a new
treatment for patients with invasive thymic epithelial
tumors.
In conclusion, we found a significant correlation be-
tween tumor angiogenesis and invasiveness in thymic
epithelial tumors. Our results also suggest that angiogen-
esis of these types of tumors might be dependent on
VEGF expression.
We thank Mrs Yasuko Tobayashi for her skillful technical
assistance and Mrs Nancy Folks for her support in preparing this
manuscript.
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